An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer

Roderich E. Schwarz, Srivani Konduri, Niranjan Awasthi, Danielle Cafasso, Margaret A. Schwarz

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Combination treatments in addition to gemcitabine have failed to improve outcomes in pancreatic cancer. We tested gemcitabine in combination with the antiendothelial agent endothelial monocyte-activating polypeptide II (EMAP II). Methods: Human pancreatic cancer cell line murine xenografts were treated with recombinant EMAP II (80 μg/kg), gemcitabine (100 mg/kg), or a combination, and survival and local tumor outcomes were studied. Results: Both EMAP II and gemcitabine inhibited tumor growth, but the combination of both was always more effective. EMAP II and gemcitabine also inhibited microvessel density, with the combination being more effective. Apoptotic activity was increased by factors of 3.2-, 2.7-, and 4.2-fold in EMAP II, gemcitabine, or their combination, respectively. There was a significant extension of survival after EMAP II and gemcitabine combination therapy compared with controls in 2 different pancreatic cancer cell line models at P = .0001 and P = .006, respectively. The median EMAP II survival contribution over gemcitabine was 16 days, from 35 to 51 days (P = .017). EMAP II had no impact on gemcitabine-induced antiproliferative effects against pancreatic cancer cells in vitro. Conclusion: The antiendothelial agent EMAP II enhanced gemcitabine-mediated tumor inhibition, pointing toward a promising strategy for improved combination treatment of pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)241-249
Number of pages9
JournalSurgery
Volume146
Issue number2
DOIs
StatePublished - Aug 2009

Fingerprint

gemcitabine
Pancreatic Neoplasms
Survival
Therapeutics
small inducible cytokine subfamily E, member 1
Cell Line
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Schwarz, R. E., Konduri, S., Awasthi, N., Cafasso, D., & Schwarz, M. A. (2009). An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer. Surgery, 146(2), 241-249. https://doi.org/10.1016/j.surg.2009.04.015

An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer. / Schwarz, Roderich E.; Konduri, Srivani; Awasthi, Niranjan; Cafasso, Danielle; Schwarz, Margaret A.

In: Surgery, Vol. 146, No. 2, 08.2009, p. 241-249.

Research output: Contribution to journalArticle

Schwarz, RE, Konduri, S, Awasthi, N, Cafasso, D & Schwarz, MA 2009, 'An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer', Surgery, vol. 146, no. 2, pp. 241-249. https://doi.org/10.1016/j.surg.2009.04.015
Schwarz, Roderich E. ; Konduri, Srivani ; Awasthi, Niranjan ; Cafasso, Danielle ; Schwarz, Margaret A. / An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer. In: Surgery. 2009 ; Vol. 146, No. 2. pp. 241-249.
@article{1940959489ab4fcba59f51d659b58c51,
title = "An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer",
abstract = "Background: Combination treatments in addition to gemcitabine have failed to improve outcomes in pancreatic cancer. We tested gemcitabine in combination with the antiendothelial agent endothelial monocyte-activating polypeptide II (EMAP II). Methods: Human pancreatic cancer cell line murine xenografts were treated with recombinant EMAP II (80 μg/kg), gemcitabine (100 mg/kg), or a combination, and survival and local tumor outcomes were studied. Results: Both EMAP II and gemcitabine inhibited tumor growth, but the combination of both was always more effective. EMAP II and gemcitabine also inhibited microvessel density, with the combination being more effective. Apoptotic activity was increased by factors of 3.2-, 2.7-, and 4.2-fold in EMAP II, gemcitabine, or their combination, respectively. There was a significant extension of survival after EMAP II and gemcitabine combination therapy compared with controls in 2 different pancreatic cancer cell line models at P = .0001 and P = .006, respectively. The median EMAP II survival contribution over gemcitabine was 16 days, from 35 to 51 days (P = .017). EMAP II had no impact on gemcitabine-induced antiproliferative effects against pancreatic cancer cells in vitro. Conclusion: The antiendothelial agent EMAP II enhanced gemcitabine-mediated tumor inhibition, pointing toward a promising strategy for improved combination treatment of pancreatic cancer.",
author = "Schwarz, {Roderich E.} and Srivani Konduri and Niranjan Awasthi and Danielle Cafasso and Schwarz, {Margaret A.}",
year = "2009",
month = "8",
doi = "10.1016/j.surg.2009.04.015",
language = "English (US)",
volume = "146",
pages = "241--249",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer

AU - Schwarz, Roderich E.

AU - Konduri, Srivani

AU - Awasthi, Niranjan

AU - Cafasso, Danielle

AU - Schwarz, Margaret A.

PY - 2009/8

Y1 - 2009/8

N2 - Background: Combination treatments in addition to gemcitabine have failed to improve outcomes in pancreatic cancer. We tested gemcitabine in combination with the antiendothelial agent endothelial monocyte-activating polypeptide II (EMAP II). Methods: Human pancreatic cancer cell line murine xenografts were treated with recombinant EMAP II (80 μg/kg), gemcitabine (100 mg/kg), or a combination, and survival and local tumor outcomes were studied. Results: Both EMAP II and gemcitabine inhibited tumor growth, but the combination of both was always more effective. EMAP II and gemcitabine also inhibited microvessel density, with the combination being more effective. Apoptotic activity was increased by factors of 3.2-, 2.7-, and 4.2-fold in EMAP II, gemcitabine, or their combination, respectively. There was a significant extension of survival after EMAP II and gemcitabine combination therapy compared with controls in 2 different pancreatic cancer cell line models at P = .0001 and P = .006, respectively. The median EMAP II survival contribution over gemcitabine was 16 days, from 35 to 51 days (P = .017). EMAP II had no impact on gemcitabine-induced antiproliferative effects against pancreatic cancer cells in vitro. Conclusion: The antiendothelial agent EMAP II enhanced gemcitabine-mediated tumor inhibition, pointing toward a promising strategy for improved combination treatment of pancreatic cancer.

AB - Background: Combination treatments in addition to gemcitabine have failed to improve outcomes in pancreatic cancer. We tested gemcitabine in combination with the antiendothelial agent endothelial monocyte-activating polypeptide II (EMAP II). Methods: Human pancreatic cancer cell line murine xenografts were treated with recombinant EMAP II (80 μg/kg), gemcitabine (100 mg/kg), or a combination, and survival and local tumor outcomes were studied. Results: Both EMAP II and gemcitabine inhibited tumor growth, but the combination of both was always more effective. EMAP II and gemcitabine also inhibited microvessel density, with the combination being more effective. Apoptotic activity was increased by factors of 3.2-, 2.7-, and 4.2-fold in EMAP II, gemcitabine, or their combination, respectively. There was a significant extension of survival after EMAP II and gemcitabine combination therapy compared with controls in 2 different pancreatic cancer cell line models at P = .0001 and P = .006, respectively. The median EMAP II survival contribution over gemcitabine was 16 days, from 35 to 51 days (P = .017). EMAP II had no impact on gemcitabine-induced antiproliferative effects against pancreatic cancer cells in vitro. Conclusion: The antiendothelial agent EMAP II enhanced gemcitabine-mediated tumor inhibition, pointing toward a promising strategy for improved combination treatment of pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=67650665789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650665789&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2009.04.015

DO - 10.1016/j.surg.2009.04.015

M3 - Article

C2 - 19628080

AN - SCOPUS:67650665789

VL - 146

SP - 241

EP - 249

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 2

ER -